Title |
Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer
|
---|---|
Published in |
Cochrane database of systematic reviews, November 2010
|
DOI | 10.1002/14651858.cd008302.pub2 |
Pubmed ID | |
Authors |
Chao Ma, Jiawei Xie, Wanxia Liu, Guoming Wang, Shuyao Zuo, Xufu Wang, Fengyu Wu |
Abstract |
For patients with differentiated thyroid cancer (DTC) following thyroidectomy, thyroid hormone withdrawal (THW) for four to six weeks has been used for decades to increase serum thyroid-stimulating hormone (TSH) concentrations in order to enhance iodine-131 uptake by normal thyroid cells and differentiated thyroid tumour cells. Exogenous stimulation with recombinant human thyroid-stimulating hormone (rhTSH) offers an alternative to THW while avoiding the morbidity of hypothyroidism. However, the efficacy of rhTSH-aided iodine-131 treatment for residual or metastatic DTC has not been prospectively assessed. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 3 | 50% |
Unknown | 3 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 83% |
Scientists | 1 | 17% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 158 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 20 | 13% |
Researcher | 19 | 12% |
Student > Master | 16 | 10% |
Student > Ph. D. Student | 15 | 9% |
Student > Doctoral Student | 8 | 5% |
Other | 29 | 18% |
Unknown | 51 | 32% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 61 | 39% |
Nursing and Health Professions | 13 | 8% |
Psychology | 8 | 5% |
Biochemistry, Genetics and Molecular Biology | 3 | 2% |
Social Sciences | 3 | 2% |
Other | 14 | 9% |
Unknown | 56 | 35% |